Phase 2 Stage IVB Prostate Cancer AJCC v8 trials recruiting now

All Stage IVB Prostate Cancer AJCC v8 trials, every phase

Other phases for Stage IVB Prostate Cancer AJCC v8

Phase 2 Stage IVB Prostate Cancer AJCC v8 trials

• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
  NCT05113537 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT05168618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06236139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
  NCT06244004 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 6 locations
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
  NCT06526299 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
  NCT07698535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
  NCT05054296 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
  NCT06288113 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT06616155 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
  NCT06039371 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
  NCT04734730 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 581 locations
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
  NCT05691465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
  NCT06145633 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.